CPIX Cumberland Pharmaceuticals Inc.

$CPIX I noticed on the last page the DMD Parent Association slide presentation on the CPIX website, that the OLE 36 -month safety and efficacy data will be available in August. With only 5 days left in August , why isn't anyone here talking about what will likely be the most important data release in the company's history?

$CPIX the major dividend was not a mistake reimbursed me on 50% of my stocks. You all have a wonderful week. Might load some around 6.50. We will see. Going on vacation this week for 2 weeks.

$CPIX holding out for the scleroderma and ipf update by eoy. At somepoint they will launch the p3 for dmd cardiomyopathy. Trading around cash value. The drug is given no value as of right now. Should trade 2x caah.

$CPIX plus if you listened to the conference call the transaction didnt close till 7/1. It will be disclosed in this 10q filing.

$CPIX Well, price action today is discouraging. The market understandably did not like the 8K this past Friday. There are a couple Stocktwit CPIX observors, BioResearcher and Willis, who are upset at an absence of promised data. Cannot say I blame them. Management might be well served to listen and respond appropriately with more transparency. I remain bullish and believe the DMD data in cardiomyopathy, is good enough to, at minimum, result in a phase 3 ready asset. I say that partly on the FDA fast track, which must have seen at least some OLE data, and partly on my interpretation of the 12 month data. But I would say the company would benefit from apprising investors what is happening with the data and FDA. So this is a plea to the company to characterize the data and make data available as soon as now...

$CPIX Management said the company set aside $5M to buy back stock and that insiders wanted to establish/renew stock purchase plans. I see no SEC filings since that announcement. Where's the beef? Where's the promised OLE 24 month data? Where'e management? Hot air? Empty promises? Inquiring minds want to know, but they ain't tellin.

$CPIX I asked Grok about peak sales potential for every pipeline asset: "DMD cardiomyopathy $500M–$1B+ Systemic sclerosis (SSc) $300–700M Idiopathic pulmonary fibrosis (IPF) $400M–$1B+ Cancer metastasis prevention $300M–$1B+ Current CPIX Enterprise value is only ~$50–60 million (market cap ~$130–134M minus ~$75–80M net cash). Full success across the pipeline would therefore represent very large upside." We only need one success to get to 50+ Enjoy the ride🤞

$CPIX CPIX read-through from today’s $CAPR extension: no change to the hard numbers — the ~$6 cash floor and ~$10 risk-adjusted fair value stand. What hardens is the conclusion: value ifetroban’s DMD leg at essentially zero. Capricor abandoned the cardiomyopathy claim and refiled on a narrowed upper-limb indication because it couldn’t get FDA to accept the LVEF/cardiac data. The best-positioned DMD-cardiac program in the industry just proved the LVEF-surrogate path impassable for now — which directly undercuts the “$CPIX gets AA for cardiomyopathy” thesis. Assign it no weight.

$CPIX IF the company announces that they will run Phase 3 on DMD, the stock is likely to drop to 2 It would take 4 years and lots of money will need to be raised, just to find out if the drug works without historical data. No one is willing to hold that long. I think that is likely the reason they keep kicking the can down the road. BUT what do I know. lol

$CPIX The stock action today is the predictable result of management consistently over promising and under delivering on expected clinical data release timelines. And announcing the latest failure AH on a Friday is the cherry on top. And while I'm venting, the Special Dividend was a mistake as cash is the holy grail of small cap bio, where you can never have too much. It should be used to aggressively push the pipeline thru clinical trials. Slow doesn't work, especially when you're fighting for Accelerated Approval in a highly unmet medical need indication like DMD cardiomyopathy. MANAGEMENT REALLY NEEDS TO SERIOUSLY STEP UP THEIR GAME!

$CPIX its true. But it does mean negative data. CAPR POLITICS is still real. Think!! Ifetroban is designed to “play well” with all standard Duchenne cardiomyopathy treatments. (ACE inhibitors, ARBs/ARNI, beta‑blockers, and MRAs)

$CPIX gogogogo hahahahaha and its up with trading restrictions at BofA folks just watching this pump!!!

$CPIX Everyone ie entitled to their point of view, Odd you would assign 10 dollars to the stock given your stated view that Ifetroban will fail in DMD cardiomyopathy. FYI, our view is that Deramiocel failed in cardiac myopathy because it showed no improvement over time in an early stage (not late stage) patient group.

$CPIX a conventional phase 3 in an orphan disease like dmd would not take 4 years. Shareholders would benefit most from a company sale at that point. The drug's safety profile, if maintained, and ease of use (a pill), and other indications,(certainly cancer) should result in sale of the company at >3x current market cap. The cancer indication should be partnered today. Maybe 50 mm in cash with milestones/royalties...

$CPIX The question is: Will Management ever release the DMD OLE data ??? Management has been kicking the can down the road since last year, I used to be bullish on this stock, but it seems like Management will never release any data either DMD, IPF, or SSC. I guess as long as they don't release data, the drug will never fail . lol Now, they sneaked out an 8K on Friday AH saying they will not release the data now, and the future release is unknown !!! Here is the slice of their presentation last year (2025) saying they would release the DMD OLE data around June 2025 !!! BUT, they never did ! This is sad ! Any thought, folks ?

$CPIX Given management's multiple investor miscommunications, I'd say the stock is not worth 2x cash. Solid management does not fail to deliver promised data. If it does fail to deliver data, it explains why. and when it will be delivered. Solid management, which lacks drug development experience, relies on a CRO to gather data, interpret data, and engage with FDA. Responsible management tells the investor base if it employs a CRO. A responsible management employs a biotech investment bank/M and A biotech law firm, thus knowing what the various indications are worth and knows to whom the company can partner or sell the indications and at what price. A responsible management characterizes the data, if the full data set is, as yet, incomplete. Despite all this the company is worth hanging onto, if you believe, as we do that, the drug's biomechanics, safety and ease of use, should position the drug for potential approval in DMD, and further drug development in Cancer, and Scleroderma.

$CPIX Not only the DMD OLE data, but the IPF and SSC data are also long overdue since their promised last year You can go back to last year 's CC and hear for yourself. DMD, IPF, and SSC are very aggressive diseases, Cell or Gene therapies may have a chance, but It is hard for CPIX' pill to treat these diseases, which is understandable, Management should be frank with investors, don't just quietly sneaked out an 8-K on Friday AH like that.

$CPIX now lone heart procedure with Capr resubmitting for upper-limb? View Capr situation as a positive for Cpix

$CPIX shocking that no one on this forum opines on Willis's CPIX concerns. It is as though there are only a handful of knowledgable people on this forum who care about this strangely managed, small biotech. We concur with Willis. We wonder if this company retains a CRO, investment banker and M and A firm to access a lawyer consultant.

$CPIX where do you see management confirmation that "it will not release Phase 2 DMD data in Sugust 2026"? I have not seen that.